Alterity Targets Mid-2026 FDA Meeting After ATH434 Shows 48% UMSARS-I Slowing
Alterity Therapeutics will hold an End-of-Phase 2 FDA meeting in mid-2026 to confirm a Phase 3 trial design for ATH434 in multiple system atrophy. Its Phase 2 data showed a 48% slowing of UMSARS-I decline at 50 mg BID (p=0.035) and significant swallowing improvement (p=0.003).
1. Phase 2 Efficacy Data
ATH434 demonstrated a 48% reduction in UMSARS-I progression versus placebo at 50 mg BID (p=0.035) and a consistent directional trend at 75 mg BID. Over 52 weeks, swallowing impairment worsened by 8.5 points on SDQ for placebo versus 1.2 and 5.0 points for 50 mg and 75 mg groups, with the 50 mg dose achieving statistical significance (p=0.003).
2. Biomarker and Imaging Advances
Quantitative Susceptibility Mapping (QSM) MRI detected progressive iron accumulation in early MSA, offering a standardizable biomarker for early diagnosis, monitoring, and trial enrichment. CSF neurofilament light (NfL) served as a prognostic covariate, with higher baseline levels predicting greater UMSARS-I decline and strengthening detection of treatment effects.
3. Phase 3 Planning and FDA Meeting
Alterity is on track for an End-of-Phase 2 meeting with FDA in mid-2026 to finalize the design of a Phase 3 trial for ATH434. The company’s novel imaging and biomarker approach will guide patient stratification and endpoint selection to optimize trial efficiency and accelerate the path toward a potential disease-modifying therapy for MSA.